Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis

Annals of Neurology

Volumn 51, Issue 6, 2002, Pages 694-702

  Feinstein, Douglas L ^a   Galea, Elena ^a   Gavrilyuk, Vitaliy ^a   Brosnan, Celia F ^b   Whitacre, Caroline C ^c   Dumitrescu Ozimek, Lucia ^d   Landreth, Gary E ^e   Pershadsingh, Harrihar A ^f   Weinberg, Guy ^a   Heneka, Michael T ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; GW 347845; I KAPPA B; MYELIN BASIC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE SEVERITY; FEMALE; IMMUNIZATION; INCIDENCE; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; SYMPTOMATOLOGY; T LYMPHOCYTE ACTIVATION;

ANIMALS; CEREBELLUM; CEREBRAL CORTEX; DNA-BINDING PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; I-KAPPA B PROTEINS; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OXAZOLES; PEPTIDE FRAGMENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REMISSION INDUCTION; SPINAL CORD; T-LYMPHOCYTES; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TYROSINE;

EID: 0036260784     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10206     Document Type: Article

References (43)

1. Kinetics and cellular origin of cytokines in the central nervous system: Insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis
2. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis
3. Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system
4. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis
5. Cuprizone and piperonyl butoxide, proposed inhibitors of T-cell function, attenuate experimental allergic encephalomyelitis in SJL mice
6. Protective effect of Rolipram in experimental autoimmune neuritis: Protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system
7. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression
8. Treatment of multiple sclerosis: Recent trials and future perspectives
9. Glatiramer acetate in the treatment of multiple sclerosis
10. Evaluation of mitoxantrone for the treatment of multiple sclerosis
11. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology
12. The PPARs: From orphan receptors to drug discovery
13. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
14. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
15. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
16. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
17. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function
18. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression
19. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta 12, 14-prostaglandin J2 in the regulation of microglial functions
20. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2
21. Peroxisome proliferator- activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
22. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma
23. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT
24. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses
25. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis
26. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture
27. The heat shock response reduces myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice
28. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis
29. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma
30. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys
31. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloidstimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
32. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis
33. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo
34. Inhibition of inducible nitric oxide synthase by peroxisome proliferator- activated receptor agonists: Correlation with induction of heme oxygenase 1
35. Induction of Ikappa-Balpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators
36. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
37. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
38. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
39. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemiareperfusion injury
40. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation
41. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease
42. Immunologic therapy of multiple sclerosis
43. 2 ameliorates experimental autoimmune encephalomyelitis